Open AccessGlycated haemoglobin: A marker of circulating lipids in patients with type 2 diabetes
Author(s) -
Sheikh Ishaq,
Iram Shabir,
Arif Akbar Bhat,
Imran Shafi,
Saima Mushtaq,
P Shah,
Azra Baba,
Sabhiya Majid
Publication year - 2017
Publication title -
journal of diabetology
Language(s) - English
Resource type - Journals
eISSN - 2543-3288
pISSN - 2078-7685
DOI - 10.4103/jod.jod_7_17
Subject(s) - medicine , type 2 diabetes mellitus , lipid profile , triglyceride , endocrinology , cholesterol , diabetes mellitus , metabolic disorder , high density lipoprotein , lipoprotein , type 2 diabetes , blood lipids , gastroenterology
Type 2 diabetes mellitus (T2DM) is a group of metabolic disorder and is an independent risk factor for cardiovascular disease and dyslipidaemia. Patients with T2DM have dyslipidaemia at wavering degrees, characterised by increased levels of triglyceride and low-density lipoprotein-cholesterol and decreased levels of high-density lipoprotein (HDL)-cholesterol. In the present study, we evaluated glycated haemoglobin (HbA1c) as a marker of circulating lipids in patients with T2DM. Methods: Two hundred and thirty-nine patients with T2DM were enrolled for the study. A detailed biochemical and lipid profile was done for all patients. Results: Of 239 cases, 96 (40%) were male and 143 (60%) were female. Of 239 patients, 53 (22%) patients with T2DM had controlled glycaemia (HbA1c <6.5) and 186 (78%) patients had uncontrolled glycaemia (HbA1c ≥6.5). Pearson's correlation of HbA1c with all lipid parameters was statistically significant. HbA1c, however, had an inverse correlation with HDL and had a significant direct correlation with fasting blood glucose. Conclusion: The study reveals that HbA1c is not only a reliable glycaemic index but can also be used as an important indicator of dyslipidaemia in patients with T2DM